From: kristoff@NET.BIO.NET (Dave Kristofferson)
Newsgroups: bionet.sci-resources
Subject: NIH Guide, vol. 21, no. 41, pt. 1, 13 November 1992
Date: 12 Nov 92 18:12:42 GMT
Distribution: bionet


NOTE: The NIH Guide may be split into more than one mail message to
avoid truncation during e-mail distribution.  The first message always
begins with the RFP/RFA summary sections followed by the appended
texts of the full RFP/RFAs.
----------------------------------------------------------------------

$$XID NIHGUIDE 19921113 V21N41 P1O3 ************************************
X-comment: RFAs described: HL-93-09, HL-93-10, AI-92-12, CA-93-03, DK-93-06

NIH GUIDE - Vol. 21, No. 41, November 13, 1992

$$INDEX BEGIN *******************************************************

                               NOTICES

$$INDEX N1 **********************************************************

NATIONAL HUMAN SUBJECT PROTECTIONS WORKSHOPS
National Institutes of Health
Food and Drug Administration
INDEX:  NATIONAL INSTITUTES OF HEALTH; FOOD AND DRUG ADMINISTRATION

               NOTICES OF AVAILABILITY (RFPs AND RFAs)

$$INDEX R1 **********************************************************

LABORATORY FOR ASSESSMENT OF MUCOSAL IMMUNE RESPONSES INDUCED BY AIDS
VACCINES IN CLINICAL TRIAL VOLUNTEERS (RFP NIAID-DAIDS-93-18)
National Institute of Allergy and Infectious Diseases
INDEX:  ALLERGY, INFECTIOUS DISEASES

$$INDEX R2 **********************************************************

BIOCHEMICAL SCREENS FOR AGENTS EFFECTIVE AGAINST AIDS-RELATED
OPPORTUNISTIC INFECTION (RFP NIAID-DAIDS-93-19)
National Institute of Allergy and Infectious Diseases
INDEX:  ALLERGY, INFECTIOUS DISEASES

$$INDEX R3 **********************************************************

GENETIC SEQUENCE VARIABILITY OF HIV-1 AND RELATED LENTIVIRUSES (RFP
NIAID-DAIDS-93-22)
National Institute of Allergy and Infectious Diseases
INDEX:  ALLERGY, INFECTIOUS DISEASES

$$INDEX R4 **********************************************************

CLINICAL TRIALS CENTER FOR ANTIHYPERTENSIVE AND LIPID-LOWERING
TREATMENT TO PREVENT HEART ATTACK TRIAL (RFP NHLBI-HC-93-44)
National Heart, Lung, and Blood Institute
INDEX:  HEART, LUNG, BLOOD

$$INDEX R5 02/17/93 *************************************************

TUBERCULOSIS ACADEMIC AWARD (RFA HL-93-09-L)
National Heart, Lung, and Blood Institute
INDEX:  HEART, LUNG, BLOOD

$$INDEX R6 02/17/93 *************************************************

ASTHMA ACADEMIC AWARD (RFA HL-93-10-L)
National Heart, Lung, and Blood Institute
INDEX:  HEART, LUNG, BLOOD

$$INDEX R7 02/18/93 *************************************************

WOMEN'S INTERAGENCY HIV STUDY (RFA AI-92-12)
National Institute of Allergy and Infectious Diseases
INDEX:  ALLERGY, INFECTIOUS DISEASES

$$INDEX R8 03/10/93 *************************************************

THERAPEUTIC STUDIES OF PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANCIES IN
ADULTS (RFA CA-93-03)
National Cancer Institute
INDEX:  CANCER

$$INDEX R9 03/15/93 *************************************************

EXPLORATORY GRANTS FOR CENTERS OF EXCELLENCE IN MOLECULAR HEMATOLOGY
(RFA DK-93-06)
National Institute of Diabetes and Digestive and Kidney Diseases
INDEX:  DIABETES, DIGESTIVE, KIDNEY DISEASES

                    ONGOING PROGRAM ANNOUNCEMENTS

$$INDEX P1 **********************************************************

MINORITY HIGH SCHOOL STUDENT RESEARCH APPRENTICE PROGRAM (PA-92-111)
National Center for Research Resources
INDEX:  RESEARCH RESOURCES

$$INDEX P2 **********************************************************

MOLECULAR AND CELLULAR BIOLOGY OF METASTATIC TUMOR CELLS (PA-93-016)
National Cancer Institute
INDEX:  CANCER

$$INDEX P3 **********************************************************

OXIDATIVE DAMAGE, ANTIOXIDANT DEFENSE, AND AGING (PA-93-017)
National Institute on Aging
INDEX:  AGING

$$INDEX P4 **********************************************************

NEURAL REGENERATION AND PLASTICITY AFTER SPINAL CORD INJURY (PA-93-018)
National Institute of Neurological Disorders and Stroke
INDEX:  NEUROLOGICAL DISORDERS, STROKE

$$INDEX P5 **********************************************************

NEUROLOGICAL BASIS OF RECURRENT HEADACHE, ESPECIALLY MIGRAINE
(PA-93-019)
National Institute of Neurological Disorders and Stroke
INDEX:  NEUROLOGICAL DISORDERS, STROKE

$$INDEX P6 **********************************************************

SMALL INSTRUMENTATION GRANTS PROGRAM (PA-93-020)
National Institutes of Health
INDEX:  NATIONAL INSTITUTES OF HEALTH

                               ERRATUM

$$INDEX E1 **********************************************************

ACADEMIC AWARD IN VASCULAR DISEASE (PAR-93-008)
National Heart, Lung, and Blood Institute
INDEX:  HEART, LUNG, BLOOD

This publication is also available electronically to institutions via
BITNET or INTERNET.  Alternative access is through the NIH Grant Line
using a personal computer.  Contact Dr. John James at 301/496-7554 for
details, or send an E-mail message to ZNS@NIHCU.

$$INDEX END *********************************************************

                               NOTICES

$$N1 BEGIN **********************************************************

NATIONAL HUMAN SUBJECT PROTECTIONS WORKSHOPS

NIH GUIDE, Volume 21, Number 41, November 13, 1992

P.T. 42; K.W. 0783005

National Institutes of Health
Food and Drug Administration

The National Institutes of Health (NIH) and the Food and Drug
Administration (FDA) are continuing to sponsor a series of workshops on
responsibilities of researchers, Institutional Review Boards (IRBs),
and institutional officials for the protection of human subjects in
research.  The workshops are open to everyone with an interest in
research involving human subjects.  The meetings should be of special
interest to those persons currently serving or about to begin serving
as a member of an IRB.  Issues discussed at these workshops are
relevant to all other Public Health Service agencies.  The current
schedule includes the following:

SOUTHWESTERN WORKSHOP

DATES:  November 16 & 17, 1992

LOCATION:
Wyndham Warwick
5701 Main Street
Houston, TX  77005
Telephone:  (713) 526-1991

SPONSORS:
University of Texas Health Science Center at Houston
Prairie View A&M University

REGISTRATION:
Ms. Paula Knudson
Executive Coordinator
Office of Research Support Committee
University of Texas Health Science Center at  Houston
P.O. Box 20036
Houston, TX  77225
Telephone:  (713) 792-5048

TITLE:  Geriatric Research as an Ethical Mandate:  Politics, Policy,
and Problems

DESCRIPTION:  Expanded life expectancies and expanding technologies are
swelling the ranks of the frail and disabled elderly.  Minimal research
has been carried out to understand the problems this subject group and
their families encounter in finding solutions to their health and
social needs.  The conference will identify key problems that need to
be studied; isolate the risks and benefits associated with behavioral,
clinical, or evaluation research designed to enroll this group as
subjects; and pose solutions that will meet the needs of regulators,
scientists, and the elderly.

The program is designed to be of interest to physicians, nurses,
pharmacists, scientific investigators, and other health care
professionals, clergy, lawyers, medical, nursing, social work students,
psychologists, and IRB members and administrators.  Attention will be
paid to Federal regulations with special emphasis on the assessment of
risks---medical, legal, and psychosocial.  Opportunities will be
available through workshops, question periods, and informal discussions
for participants to exchange ideas and interests with faculty and OPRR
and FDA representatives.

SOUTHEASTERN WORKSHOP

DATES:  January 14 & 15, 1993

LOCATION:
Sheraton Sand Key Resort
1160 Gulf Boulevard
Clearwater Beach, FL  33515
Telephone:  (813) 595-1611

SPONSORS:
University of South Florida
Florida A & M University

REGISTRATION:
Ms. Eileen Highsmith
Executive Secretary
University of South Florida
4202 E. Fowler Avenue (MP.FAO-126)
Tampa, FL  33620-7900
Telephone:  (813) 974-2897

TITLE:  Barriers to Informed Consent:  Language, Age Factors, Trauma,
and Women/Minority Issues

DESCRIPTION:  Today's researchers face numerous barriers to obtaining
an informed consent.  Such issues as age, language, mental capacity,
and sobriety may affect the ability of subjects to give a truly
informed consent.  Many of these barriers oftentimes impact the pool of
subjects which an investigator is willing (or able) to use in a
research project.  In addition, recent legislation from the Congress
was designed to address the issue of inadequate numbers of women and
minorities in research projects.  This conference has been designed to
address three main areas in which barriers to informed consent may
exist:  mental competence, ethnic and gender issues, and research with
children and the elderly.

The conference program is designed to be of value to physicians,
nurses, pharmacists, scientific investigators, and other health care
professionals.  All IRB members, students in health care areas and
administrators will also benefit from the conference.  Attention will
be given to Federal regulations governing research on human subjects,
with special emphasis placed on the assessment of risks---medical,
legal, and psychosocial.  Ample opportunities will be provided to
exchange ideas and interests, through question and answer sessions and
informal discussions.

For further information regarding these workshop and future NIH/FDA
National Human Subject Protections Workshops, please contact:

Ms. Darlene Marie Ross
Division of Human Subject Protections
Office for Protection from Research Risks
National Institutes of Health
Building 31, Room 5B59
Bethesda, MD  20892
Telephone:  (301) 496-8101

$$N1 END ************************************************************

               NOTICES OF AVAILABILITY (RFPs AND RFAs)

$$R1 BEGIN RFP NIAID-DAIDS-93-18 ************************************

LABORATORY FOR ASSESSMENT OF MUCOSAL IMMUNE RESPONSES INDUCED BY AIDS
VACCINES IN CLINICAL TRIAL VOLUNTEERS

NIH GUIDE, Volume 21, Number 41, November 13, 1992

RFP AVAILABLE:  NIAID-DAIDS-93-18

P.T. 34; K.W. 0715008, 0740075, 0755010, 0710070

National Institute of Allergy and Infectious Diseases

The National Institute of Allergy and Infectious Diseases (NIAID), NIH,
has a requirement to provide for the centralized performance of
immunological assays to evaluate HIV-specific humoral and cellular
mucosal immune responses in support of clinical trials of prototype
AIDS vaccines.  The purpose of this contract is to support the NIAID in
its mission to stimulate research towards discovery and testing of
prototype vaccines for the acquired immunodeficiency syndrome (AIDS).
The NIAID requires a Mucosal Immunology Laboratory to evaluate
reproductive tract, gut, blood, and other mucosal specimens from
vaccine clinical trial volunteers for humoral and cellular mucosal
immune responses induced by immunization with prototype AIDS vaccines.
This effort will support the research of AIDS investigators, including
the AIDS Vaccine Evaluation Group (AVEG), the National Cooperative
Vaccine Evaluation Groups (NCVDG), and other programs initiated by
NIAID.

Specifically, the selected Contractor shall be responsible for:  (1)
performing specific immunological assays for detection of HIV-specific
antibody and cellular responses in mucosal site and blood specimens
from AIDS vaccine recipients; (2) developing standard protocols for the
collection, processing, and storage of mucosal specimens at the vaccine
trial sites; (3) receiving, cataloging, tracking, coding, storing, and
maintaining an inventory of vaccinee specimens arriving for evaluation;
and (4) maintaining a test result database and transferring data
electronically to the AIDS Vaccine Clinical Trials Network (AVCTN) Data
Coordinating and Analysis Center (DCAC).

This is an announcement for an anticipated Request for Proposals (RFP).
RFP:  NIH-NIAID-DAIDS-93-18 will be issued on or about November 13,
1992 with a closing date tentatively set for January 5, 1993.  It is
expected that one (1) contract will be awarded as a result of this
solicitation.  It is expected that the contract will have a five-year
period of performance, and a completion type cost-reimbursement
contract is anticipated.

INQUIRIES

Requests for the RFP may be directed in writing to:

Lawrence Butler, Contracting Officer
Contract Management Branch
National Institute of Allergy and Infectious Diseases
Solar Building, Room 3C-07
6003 Executive Boulevard
Bethesda, MD  20892

Please provide this office with three self-addressed mailing labels.
Telephone
inquiries will not be honored and all inquiries must be in writing.  A
short-form version of the RFP will be provided first, which includes
only the statement of work and the Evaluation Criteria to be used for
selection of the awardee.

After examining this, a full-text version of the RFP must be requested
in writing by those offerors interested in responding.  FAX requests
are acceptable for the full-text version of the RFP only (FAX:
301-402-0972).  All proposals from responsible sources will be
considered by the NIAID.  This advertisement does not commit the
Government to award a contract.

$$R1 END ************************************************************

$$R2 BEGIN RFP NIAID-DAIDS-93-19 ************************************

BIOCHEMICAL SCREENS FOR AGENTS EFFECTIVE AGAINST AIDS-RELATED
OPPORTUNISTIC INFECTION

NIH GUIDE, Volume 21, Number 41, November 13, 1992

RFP:  NIAID-DAIDS-93-19

P.T. 34; K.W. 0755010, 0715008, 0755060, 0760013

National Institute of Allergy and Infectious Diseases

The Developmental Therapeutics Branch, Basic Research and Development
Program, Division of AIDS, National Institute of Allergy and Infectious
Disease (NIAID), NIH has a requirement to apply established
biochemically-based enzymatic or non-enzymatic assays to screen agents
for inhibition of one or more steps in the metabolism of
AIDS-associated opportunistic pathogens.  These biochemical prescreens
are considered particularly useful for rapid testing of compounds.
Examples of such assays may include, but not be limited to:  protein
synthesis, dihydrofolate reductase, and dihydropteroate synthase. The
major effort of this contract will involve the screening of a large
number of compounds.  A secondary focus of this contract will be
development/modification of automated biochemical assays and their
application to drug testing against opportunistic infections in AIDS.
It is anticipated that some assays will require isolation of enzymes
from relevant microorganisms or cloning to obtain the protein.
However, most of the enzymes and recombinant proteins required for the
development of assays in this project will be provided by the AIDS
Reference and Reagent Repository.  Other non-enzymatic assays may be
developed /used to evaluate drug activities in vitro.  At the present
time, NIAID has one contract that is scheduled to end in 1993 to screen
agents in enzymatic assays.

This NIAID sponsored project will take approximately three years to
complete.  A level-of-effort, cost reimbursement contract is
anticipated.  It is expected that one award will be made.

This is an announcement for an anticipated Request for Proposal (RFP).
RFP NIH-NIAID-DAIDS-93-19 will
be issued on or about November 12, 1992, with a closing date
tentatively set for January 15, 1993.

INQUIRIES

Requests for the RFP may be directed in writing to:

Cyndie Cotter
Contract Management Branch
National Institute of Allergy and Infectious Diseases
Solar Building, Room 3C07
6003 Executive Boulevard
Bethesda, MD  20892

To receive a copy of the RFP, please supply this office with three
self-addressed mailing labels.  Telephone inquiries will not be honored
and all inquiries must be in writing.  A short- form version of the RFP
will be provided first, which includes only the Statement of Work and
the Evaluation Criteria to be used for selection of the awardee.  After
examining this, a full-text version of the RFP must be requested, in
writing, for those offerors interested in responding.  FAX requests are
acceptable for the full-text version only (FAX:  301-402-0972).  All
proposals from responsible sources will be considered by the NIAID.
This advertisement does not commit the Government to award a contract.

$$R2 END ************************************************************

$$R3 BEGIN RFP NIAID-DAIDS-93-22 ************************************

GENETIC SEQUENCE VARIABILITY OF HIV-1 AND RELATED LENTIVIRUSES

NIH GUIDE, Volume 21, Number 41, November 13, 1992

RFP:  NIH-NIAID-DAIDS-93-22

P.T. 34; K.W. 1215018, 0755018

National Institute of Allergy and Infectious Diseases

The National Institute of Allergy and Infectious Diseases (NIAID), NIH,
has a requirement for a contractor to receive samples infected with
HIV-1 or related lentiviruses, to amplify virus-specific genetic
sequences from these samples, and to clone and sequence these amplified
fragments.  The Contractor will be required to design gene
amplification primers for distinct regions of the virus genome and for
diverse viral isolates.  The Contractor will be required to amplify and
clone sizable genomic fragments (>1500 base pairs), and carry out
large-scale genetic sequencing (approximately 200,000 bases/year).

Specifically, the selected contractor shall be responsible for:  (1)
amplifying, cloning and sequencing HIV-1 and related
lentivirus-specific gene fragments from samples derived from
HIV-infected individuals provided through the Project Officer; (2)
compiling and analyzing genetic sequence data, and transferring data to
the HIV Genetic Sequence Database and Analysis Unit at the Los Alamos
National Laboratory; (3) receiving, cataloging, processing, storing
samples, and distributing samples to other investigators; and (4)
providing an Inventory and Database Management System.

This is an announcement for an anticipated Request for Proposals (RFP).
RFP NIH-NIAID-DAIDS-93-22 will be issued on or about November 9, 1992,
with a closing date tentatively set for January 5, 1993.  One contract
will be awarded as a result of this solicitation.  It is expected that
the contract will have a five-year period of performance.  A
level-of-effort cost-reimbursement contract is anticipated.

INQUIRIES

Requests for the RFP are to be directed in writing to:

Kristiane E. Hofacker, Contract Specialist
Contract Management Branch
National Institute of Allergy and Infectious Diseases
Solar Building, Room 3C07
Bethesda, MD  20892

Please provide this office with three self-addressed mailing labels.
Telephone inquiries will not be honored and all inquiries must be in
writing.  A short-form version of the RFP will be provided first, this
includes only the Statement of Work and the Evaluation Criteria to be
used for selection of the awardee.  After examining this, a full-text
version of the RFP must be requested, in writing, for those offerors
interested in responding.  FAX requests are acceptable for full-text
versions of the RFP only (FAX: 301/402-0972).  All proposals from
responsible sources will be considered by the NIAID.  This
advertisement does not commit the Government to award a contract.

$$R3 END ************************************************************

$$R4 BEGIN RFP NHLBI-HC-93-44 ***************************************

CLINICAL TRIALS CENTER FOR ANTIHYPERTENSIVE AND LIPID-LOWERING
TREATMENT TO PREVENT HEART ATTACK TRIAL

NIH GUIDE, Volume 21, Number 41, November 13, 1992

RFP AVAILABLE:  NHLBI-HC-93-44

P.T. 34; K.W. 0715115, 0755015, 0740025

National Heart, Lung, and Blood Institute

The primary purpose of this program is to select a Clinical Trials
Center to conduct a practice-based, randomized clinical trial of
antihypertensive pharmacologic treatment and, in a specific subset,
lipid-lowering, in a factorial design.  The purpose of the
antihypertensive trial is to determine whether or not the combined
incidence of fatal coronary heart disease (CHD) and non-fatal
myocardial infarction differs between diuretic-based and alternative
antihypertensive pharmacologic treatment in patients broadly
representative of the U.S. hypertensive population, including at least
55 percent African-Americans.  The purpose of the lipid-lowering trial
is to conduct, in a subset of this population and in a factorial
design, a placebo-controlled randomized clinical trial to determine
whether or not lowering serum cholesterol in older, moderately
hypercholesterolemic men and women with a 3-hydroxymethylglutaryl
coenzyme A (HMG CoA) reductase inhibitor will reduce the combined
incidence of fatal CHD and non-fatal myocardial infarction.  Rather
than using independently funded clinics, patients will be recruited
through office-based practices and hypertension clinics that will be
reimbursed by the Clinical Trials Center on a per-patient basis.  The
study will consist of a vanguard phase and a full-scale trial phase.
Six hundred patients will be entered into the vanguard phase;
approximately 30,000 patients will be enrolled in the full-scale trial.

This is not a Request for Proposals (RFP).  RFP NHLBI-HC-93-44 will be
released on or about November 6, 1992 with proposals due on or about
January 15, 1993.  One incrementally funded contract is anticipated to
be awarded for nine years.  Written requests must include three
self-addressed mailing labels and must cite RFP NHLBI-HC-93-44.

Requests for copies of the RFP are to be sent to:

Kristee M. Camilletti, Contracting Officer
HLVD Contracts Section, Contracts Operations Branch, DEA
National Heart, Lung, and Blood Institute
Federal Building, Room 4C04
Bethesda, MD  20892

$$R4 END ************************************************************

$$R5 BEGIN HL-93-09 FULL-TEXT ***************************************

TUBERCULOSIS ACADEMIC AWARD

NIH GUIDE, Volume 21, Number 41, November 13, 1992

RFA AVAILABLE:  HL-93-09-L

P.T. 34; K.W. 0715165, 0502024, 0785035

National Heart, Lung, and Blood Institute

Letter of Intent Receipt Date:  December 15, 1992
Application Receipt Date:  February 17, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

The primary objective of this program is to stimulate the development
and/or improvement of the quality of medical curricula,
physician/patient/and community education, and clinical practice for
the prevention, management, and control of Mycobacterial tuberculosis
(TB) in the United States.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Tuberculosis Academic Award, is related to the priority areas of
immunization and infectious diseases and HIV infection.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report:
Stock No. 017- 001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, DC 20402-9325 (telephone:
202-783-3238).

ELIGIBILITY REQUIREMENTS

Institutions

Applications may be submitted by domestic universities or schools of
medicine.  Minority institutions and urban institutions from areas with
high rates of incidence of TB that have the necessary resources and
facilities and a commitment to providing the awardee with the time to
develop and implement plans consistent with the goals of this
announcement are encouraged to sponsor candidates for these awards.

Candidates

A candidate for an award must:

o  be an established physician and a medical faculty member in an
accredited school of medicine or osteopathy in the United States, its
territories or possessions, and have competence in tuberculosis and;

o  be employed by a school of medicine or osteopathy that is located in
an area with high TB rates;

o  have sufficient clinical training, research, and teaching experience
in the control of TB to develop and implement a high quality curriculum
in TB encompassing current knowledge and methods applicable to the
control of tuberculosis in individuals of all ages and to provide
leadership in research in control of TB;

o  be a citizen or non-citizen national of the United States or have
been lawfully admitted to the United States for permanent residence at
the time of application;

Individuals who have held another NIH career development award (K
series) are eligible to apply for the Tuberculosis Academic Award.
Applications from minority individuals and women are encouraged.

MECHANISM OF SUPPORT

This RFA is part of the Academic Award Program (K07) of the National
Heart, Lung, and Blood Institute (NHLBI).  Responsibility for the
planning, direction, and execution of the proposed project will be
solely that of the applicant.  The total project period may not exceed
five years and is non-renewable.  It is anticipated that support for
this program will begin September 1993.

FUNDS AVAILABLE

The estimated funds (total costs) for the first year of support for the
entire program will be $300,000.  It is anticipated that three to four
grants will be awarded each year for five years under this program.
The specific number, however, will depend upon the merit and scope of
the applications received and the availability of funds.

A maximum of $50,000 for the salary of the awardee, plus applicable
fringe benefits, a maximum of $20,000 for technical support, and
indirect costs not to exceed eight percent may be requested.

OBJECTIVES

The objectives of the Tuberculosis Academic Award are to:

o  encourage the development of high quality curricula in schools of
medicine that will significantly increase the opportunities for
students, house staff, and others, including practicing physicians, to
learn the principles and practice of preventing, managing, and
controlling TB;

o  encourage research in the control of TB;

o  encourage the development of a faculty capable of providing
appropriate instruction in TB;

o  contribute to updating the knowledge and skill of practicing
physicians and other health care providers in the community;

o  enhance awareness of health care providers of the unique ethnic,
cultural, socioeconomic, and medical dimensions of TB;

o  coordinate and collaborate with other community organizations to
control TB in areas with high incidence of TB;

o  facilitate an interchange of ideas and methods among awardees and
institutions;

o  cooperate and collaborate with other organizations that have
responsibility for and interest in TB control, for example, health
departments, medical and nursing associations, and voluntary health
agencies; and

o  contribute to public health efforts to control TB in the community.

Of particular interest are programs targeted to inner city populations
and to rural areas that may be in need of education about TB and among
physicians who are or who will be caring for medically underserved
populations.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.

LETTER OF INTENT

Prospective applicants are asked to submit, by December 15, 1992, a
letter of intent that includes the name, address, and telephone number
of the Principal Investigator, the identities of other key personnel
and participating institutions, and the number and title of the RFA in
response to which the application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
that it contains is helpful in planning for the review of applications.
It allows the Institute staff to estimate the potential review workload
and to avoid conflict of interest in the review.

The letter of intent is to be sent to:

C. James Scheirer, Ph.D.
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 548B
Bethesda, MD  20892
Telephone:  (301) 496-7363

APPLICATION PROCEDURES

Applications must be received by February 17, 1993.

Applications are to be submitted on the grant application form PHS 398
(rev. 9/91).  Application kits are available at most institutional
offices of sponsored research and may be obtained from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone
301-496-7441.

REVIEW CONSIDERATIONS

Applications for this Tuberculosis Academic Award will be evaluated in
terms of the following criteria:

o  the overall merit of the proposed five-year plan for improving the
institution's interdepartmental curricula on tuberculosis;

o  the qualifications and background of the candidate, including
experience in teaching, curriculum development, and research;

o  the institution's commitment to implement the proposed curriculum
and to continue a program in education about tuberculosis control after
the termination of the award;

o  the involvement of appropriate disciplines in the development,
implementation, and evaluation of the program;

o  design and evaluation plans for educational interventions for health
care providers and for patients with tuberculosis, especially in areas
with high incidence of TB;

o  plans for communication and cooperation between specialists in adult
and pediatric pulmonary medicine, infections, and community medicine to
ensure optimal treatment;

o  plans for collaborative projects with other organizations that have
responsibility for and interest in tuberculosis control, for example,
health departments, medical and nursing associations, and voluntary
health agencies;

o  the potential of the program for making an impact on the control of
tuberculosis among populations served;

o  the potential for replication or adaptation of the program at other
sites.

Of particular interest are programs targeted to inner city populations
and to rural areas that may be in need of education about TB and among
physicians who are or who will be caring for medically underserved
populations.

INQUIRIES

Guidelines for this RFA are available from the person named below.
Written and telephone inquiries concerning this announcement are
encouraged.  The opportunity to clarify any issues or questions from
potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Joan M. Wolle, Ph.D., M.P.H.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
Westwood Building, Room 640
Bethesda, MD  20892
Telephone:  (301) 496-7668

Direct inquiries regarding fiscal matters to:

Raymond L. Zimmerman
Grants Operations Branch
National Heart, Lung, and Blood Institute
Westwood Building, Room 4A17
Bethesda, MD  20892
Telephone:  (301) 496-4970

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No. 93.838.  Grants will be awarded under the authorization of the
Public Health Service Act, Title III, Section 301 (Public Law 78-410,
as amended by Public Law 99-158, 42 US 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CAR 52 and 45 CAR
Part 74.  This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or to a review by a Health
Systems Agency.

$$R5 END ************************************************************

$$R6 BEGIN HL-93-10 FULL-TEXT ***************************************

ASTHMA ACADEMIC AWARD

NIH GUIDE, Volume 21, Number 41, November 13, 1992

RFA AVAILABLE:  HL-93-10-L

P.T. 34; K.W. 0715013, 0502024, 0785035

National Heart, Lung, and Blood Institute

Letter of Intent Receipt Date:  December 15, 1992
Application Receipt Date:  February 17, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

The primary objective of this RFA is to stimulate the development
and/or improvement of the quality of curricula, physician/patient/and
community education, and clinical practice for the prevention,
management, and control of asthma in the United States.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Asthma Academic Award, is related to the priority areas of diabetes and
chronic disabling diseases.  Potential applicants may obtain a copy of
"Healthy People 2000" (Full Report:  Stock No. 017-001-00474-0) or
"Healthy People 2000" (Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone: 202-783-3238).

ELIGIBILITY REQUIREMENTS

Institutions

Applications may be submitted by domestic universities or schools of
medicine.  Minority institutions and urban institutions from areas with
high rates of morbidity of asthma that have the necessary resources and
facilities and a commitment to providing the awardee with the time to
develop and implement plans consistent with the goals of this
announcement are encouraged to sponsor candidates for these awards.

Candidates

A candidate for an award must:

o  be an established physician and medical faculty member in an
accredited school of medicine or osteopathy in the United States, its
territories or possessions, and have competence in the management of
asthma, and;

o  be employed by a school of medicine or osteopathy that is located in
an area with high asthma morbidity, such as an institution located in
an inner city;

o  have sufficient clinical training, research, and teaching experience
in pulmonary medicine to develop and implement a high quality
curriculum in asthma encompassing current knowledge and methods
applicable to the control of asthma in individuals of all ages and to
provide leadership in applied research in control of asthma;

o  be a citizen or non-citizen national of the United States or have
been lawfully admitted to the United States for permanent residence at
the time of application;

Individuals who have held another NIH career development award (K
series) are eligible to apply for the Asthma Academic Award.
Applications from minority individuals and women are encouraged.

MECHANISM OF SUPPORT

This RFA is part of the Academic Award Program (K07) of the National
Heart, Lung, and Blood Institute (NHLBI).  Responsibility for the
planning, direction, and execution of the proposed project will be
solely that of the applicant.  The total project period may not exceed
five years and is non-renewable.  It is anticipated that support for
this program will begin September 1993.

A maximum of $50,000 for the salary of the awardee, plus applicable
fringe benefits, a maximum of $20,000 for technical support, and
indirect costs not to exceed eight percent may be requested.

FUNDS AVAILABLE

The estimated funds (total costs) for the first year of support for the
entire program will be $300,000.  It is anticipated that three to four
grants will be awarded each year for five years under this program.
The specific number, however, will depend upon the merit and scope of
the applications received and the availability of funds.

OBJECTIVES

The objectives of the Asthma Academic Award are:

o  to encourage the development of high quality curricula in schools of
medicine that will significantly increase the opportunities for
students, house staff, and others to learn the principles and practice
of preventing, managing, and controlling asthma;

o  to develop and implement interdepartmental programs with common
goals and standardize diagnostic and therapeutic approaches;

o  to promote communication among specialists in primary care, allergy,
and obstetrics and gynecology to ensure appropriate treatment of
pregnant women with asthma;

o  to encourage research in the control of asthma;

o  to promote the development of a faculty capable of providing
appropriate instruction in asthma;

o  to promote an institutional environment that facilitates an
interchange of information and educational evaluation techniques about
new diagnostic, therapeutic and prevention measures in asthma in both
children and adult populations;

o  to investigate coordinated clinical approaches to the care of
patients of various ages and ethnic groups who have asthma, such as
minorities, young children, and the elderly;

o  to provide for outreach programs from medical centers to health
practitioners in the community to enhance optimal care, especially in
areas of high asthma morbidity, such as inner city minority
communities;

o  to facilitate an interchange of ideas among awardees and
institutions;

o  to contribute to public health efforts to control asthma in the
United States.

Of particular interest are programs targeted to inner city populations
and to rural areas that may be in need of education about asthma and
among physicians who are or who will be caring for medically
underserved populations.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.

LETTER OF INTENT

Prospective applicants are asked to submit, by December 15, 1992, a
letter of intent that includes the name, address, and telephone number
of the Principal Investigator, the identities of other key personnel
and participating institutions, and the number and title of the RFA in
response to which the application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
that it contains is helpful in planning for the review of applications.
It allows the Institute staff to estimate the potential review workload
and to avoid conflict of interest in the review.

The letter of intent is to be sent to:

C. James Scheirer, Ph.D.
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 548B
Bethesda, MD  20892
Telephone:  (301) 496-7383

APPLICATION PROCEDURES

Applications must be received by February 17, 1993.

Applications are to be submitted on the grant application form PHS 398
(rev. 9/91).  Application kits are available at most institutional
offices of sponsored research and may be obtained from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone
301/496-7441.

REVIEW CONSIDERATIONS

Applications for this Asthma Academic Award will be evaluated in terms
of the following criteria:

o  the overall merit of the proposed five-year plan for improving the
institution's interdepartmental curricula in asthma control;

o  the qualifications and background of the candidate, including
experience in teaching, curriculum development, and research;

o  the institution's commitment to implement the proposed curriculum
and to continue a program in education about asthma control after the
termination of the award;

o  the involvement of appropriate disciplines in the development,
implementation, and evaluation of the program;

o  design and evaluation plans for educational interventions for health
care providers and for patients with asthma, especially in areas with
high morbidity from asthma, such as inner city minority communities;

o  plans for communication and cooperation between specialists in adult
and pediatric pulmonary medicine, family practice, internal medicine,
community medicine, and other specialties;

o  plans for collaborative projects with other organizations that have
responsibility for and interest in asthma control, for example, health
departments, medical and nursing associations, and voluntary health
agencies;

o  the potential of the program for making an impact on the control of
asthma among populations served;

o  the potential for replication or adaptation of the program at other
sites.

INQUIRIES

Guidelines for this RFA are available from the person named below.
Written and telephone inquiries concerning this announcement are
encouraged.  The opportunity to clarify any issues or questions from
potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Joan M. Wolle, Ph.D., M.P.H.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
Westwood Building, Room 640
Bethesda, MD  20892
Telephone:  (301) 496-7668

Direct inquiries regarding fiscal matters to:

Raymond L. Zimmerman
Grants Operations Branch
National Heart, Lung, and Blood Institute
Westwood Building, Room 4A17
Bethesda, MD  20892
Telephone:  (301) 496-4970

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No. 93.838.  Grants are made under the authorization of the Public
Health Service Act, Title III, Section 301 (Public Law 78-410, as
amended by Public Law 99-158, 42 US 241 and 285) and administered under
PHS grants policies and Federal Regulations 42 CAR 52 and 45 CAR Part
74.  This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Heath Systems Agency review.

$$R6 END ************************************************************

$$R7 BEGIN AI-92-12 FULL-TEXT ***************************************

WOMEN'S INTERAGENCY HIV STUDY

NIH GUIDE, Volume 21, Number 41, November 13, 1992

RFA AVAILABLE:  AI-92-12

P.T. 34, II; K.W. 0715008, 0740075, 0411005, 0403004, 0785035

National Institute of Allergy and Infectious Diseases

Letter of Intent Receipt Date:  January 11, 1993
Application Receipt Date:  February 18, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

The Vaccine Trials and Epidemiology Branch (VTEB) of the Division of
AIDS (DAIDS) of the National Institute of Allergy and Infectious
Diseases (NIAID) invites applications for cooperative agreements for
the establishment of a Women's Interagency HIV Study (WIHS) to
investigate the clinical, laboratory, and psychosocial impact of human
immunodeficiency virus (HIV) infection in women.  The WIHS will use a
multi-site, prospective study design to gather data on the clinical,
immunological, virological, and behavioral aspects of HIV infection and
disease in women.  This study will investigate the full spectrum of
clinical disease caused by HIV infection in women.  It also will seek
to determine other cofactors that may be associated with HIV disease
progression in women.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA, for
the Women's Interagency HIV Study, is related to the priority area of
HIV infection.  Potential applicants may obtain a copy of "Healthy
People 2000" (Full Report:  Stock No. 017-001-00474-0) or "Healthy
People 2000" (Summary Report:  Stock No. 017-001-10473-1) through the
Superintendent of Documents, Government Printing Office, Washington, DC
20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic non-profit, and for-profit
research institutions; public and private organizations such as
universities, colleges, hospitals or laboratories; units of State and
local governments; and eligible agencies of the Federal government.
Applications from minority individuals and women are encouraged.

Applicants must demonstrate the capability to recruit and maintain a
minimum of 300 HIV-seropositive women and 75 HIV-seronegative women who
engage in activities that put them at high risk of acquiring HIV
infection; the proposed study population should reflect the
socioeconomic, racial, and ethnic female populations infected with HIV.

MECHANISM OF SUPPORT

Applications funded under this RFA will be supported through the
National Institutes of Health (NIH) cooperative agreement (U01).
Cooperative agreements are awarded to institutions when it is desired
to encourage investigator-initiated research in areas of special
importance to the NIH and where substantial programmatic involvement by
NIH staff is anticipated.  The interaction of NIAID staff with the
investigators is expected to assist and facilitate the research.  This
RFA represents a single competition with a specified deadline for
receipt of applications.  Reissuance of this RFA will be dependent on
the state of science and findings at the completion of this cooperative
agreement, as well as the availability of funds.

FUNDS AVAILABLE

Approximately $5,000,000 will be available for funding the total costs
of the WIHS during its initial year.  The earliest possible award date
is July, 1993.  The NIAID anticipates making two to five awards as a
result of this RFA.  The final number of awards to be made is dependent
upon receipt of a sufficient number of applications of high scientific
merit and the continuing availability of funds.

BACKGROUND

The number of cases of Acquired Immunodeficiency Syndrome (AIDS)
diagnosed in women has increased rapidly since 1985. As of June 1992,
more than 24,000 cases of AIDS in women had been reported to the
Centers for Disease Control (CDC); in sharp contrast to the
approximately 1,100 women reported by the end of 1985.  Approximately
100,000 American women are estimated to be infected with HIV-1.  These
numbers are expected to continue to increase throughout the 1990s.
Major deficiencies remain in understanding the clinical, immunological,
and virological spectrum of HIV disease and AIDS in women.
Gynecological manifestations of HIV infection have not been
sufficiently studied despite early results indicating their importance.
On the basis of these early reports, women-specific disease outcomes
have been identified, suggesting the need for a large-scale prospective
study of HIV infection and disease in women to address the multiplicity
of research questions within a single research design.

The primary purpose of this RFA is to develop a cooperative multi-site
prospective epidemiologic study of the clinical, immunologic, and
virologic and behaviorally-associated aspects of HIV disease
progression in women.  The CDC and NIAID have initiated the initial
phase of this interagency prospective study of HIV-infected and
uninfected women through the CDC's 1991 program announcement No. 115
(see Federal Register, vol. 56, no. 65, Thursday, April 4, 1991), the
HIV Epidemiology Research Study (HERS).  The data collection
instruments (medical history intake questionnaires, physical exam
protocols, and laboratory specimen collection forms) for this phase of
the study are being developed collaboratively between the CDC, NIAID,
the four currently funded clinical sites, and an interim data center.
The data collection instruments developed for the HERS are available on
request by faxing your request to Dr. Sandra Melnick at (301) 402-1506.
When new sites are awarded under this RFA awardees will collaborate
with the investigators from the CDC HERS sites to review the study data
collection instruments and physical examination protocols, to arrive at
compatible data collection procedures.

RESEARCH OBJECTIVES

The overall objectives of this project are to:

o  Describe the spectrum and course of the clinical manifestations of
HIV infection in women, including those which may occur in the genital
tract and oral cavity.

o  Describe the pattern and rate of decline of CD4+ cells in women and
its relationship to other immunologic and virologic parameters, and to
the clinical manifestations of HIV.

o  Investigate factors (e.g., infectious, treatment-related,
nutritional, socioeconomic, drug-use related) which may delay or may
accelerate HIV-induced immune dysfunction and specific manifestations
of HIV-associated clinical disease.

o  Study the length of survival and quality of life of women living
with HIV infection.

Although the emphasis of this study is not on transmission of HIV, it
will still be important to follow the initially HIV-seronegative women
to:

o  Determine the rate of incident HIV seroconversion and factors that
may increase the risk of incident HIV infection among a smaller cohort
of women who are HIV-antibody negative at the time of study enrollment.
Such factors may include age, race, and ethnicity.

o  Assess the feasibility of HIV vaccine trial initiation in
HIV-seronegative women by assessing willingness to participate in
vaccine efficacy trials.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH policy is that applicants for NIH clinical research grants and
cooperative agreements will be required to include minorities and women
in study populations so that research findings can be of benefit to all
persons at risk of the disease, disorder or condition under study;
special emphasis should be placed on the need for inclusion of
minorities and women in studies of diseases, disorders and conditions
which disproportionately affect them.  This policy is intended to apply
to males and females of all ages.  If women or minorities are excluded
or inadequately represented in clinical research, particularly in
proposed population-based studies, a clear compelling rationale should
be provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of the
study.  This information should be included in the form PHS 398 in
Sections 1-4 of the Research Plan AND summarized in Section 5, Human
Subjects.

Applicants are urged to assess carefully the feasibility of including
the broadest possible representation of minority groups.  However, NIH
recognizes that it may not be feasible or appropriate in all research
projects to include representation of the full array of United States
racial/ethnic minority populations (i.e., Native Americans (including
American Indians or Alaskan Natives), Asian/Pacific Islanders, Blacks,
Hispanics).

The rationale for studies on single minority population groups should
be provided.

For the purpose of this policy, clinical research includes human
biomedical and behavioral studies of etiology, epidemiology, prevention
(and preventive strategies), diagnosis, or treatment of diseases,
disorders or conditions, including but not limited to clinical trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.

If the required information is not contained within the application,
the application will be returned.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in
assigning the priority score to the application.

All applications for clinical research submitted to NIH are required to
address these policies.  NIH funding components will not award grants
or cooperative agreements that do not comply with these policies.

NOTE:  This study fully meets the requirements for inclusion of women,
in that it is exclusively comprised of female subjects.

LETTER OF INTENT

Prospective applicants are asked to submit, by January 11,1993, a
letter of intent that includes a descriptive title of the proposed
research the name, address and telephone number of the Principal
Investigator; the identities of other key personnel and participating
institutions; and the number and title of the RFA in response to which
the application may be submitted.  The letter of intent is requested to
provide an indication of the number and scope of applications to be
reviewed.  The letter of intent does not commit the sender to submit an
application, nor is it a requirement for submission of an application.

The letter of intent is to sent to

Dr. Sandra Melnick
Vaccine Trials and Epidemiology Branch
Division of AIDS
National Institute of Allergy and Infectious Diseases
Solar Building, Room 2A28
6003 Executive Boulevard
Bethesda, MD  20892

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 9/91)is to used in
applying for these cooperative agreements.

These forms are available from the institutional offices of sponsored
research and Office of Grants Inquiries, Division of Research Grants,
National Institutes of Health, 5333 Westbard Avenue, Room 449,
Bethesda, Maryland 20892, telephone 301/496-7441.

The RFA label available in the PHS 398 application form must be affixed
to the bottom of the face page of the application.  Failure to use this
label could result in delayed processing of the application such that
it may not reach the review committee in time for review.  In addition,
"WOMEN'S INTERAGENCY HIV STUDY", RFA AI-92-12 should be typed on line
2a of the face page of the application form and the "YES" box should be
marked.

Submit a signed, typewritten original of the application, including the
checklist, and three signed, identical single-sided photocopies, in one
package, to

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

At the time of submission, two additional copies must be sent directly
to

Dr. Dianne Tingley
AIDS RRS/SRB/DEA
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 4C16
Bethesda, MD  20892

Applications must be received by both the Division of Research Grants
(DRG) and Dr. Tingley by February 18, 1993.  Applications received
after February 18, 1993 will be returned to the applicant without
review.

REVIEW CONSIDERATIONS

This application must be directed toward the objectives identified in
the RFA.  The primary factors that will be considered in the review of
the application will be the demonstrated ability or potential to
achieve the recruitment and retention goals, scientific merit of the
research plans, and the capability to participate in this multicenter
study.  The RFA contains important additional information about review
procedures and criteria.

AWARD CRITERIA

Scientific merit and technical proficiency, based on priority scores
assigned by the scientific review group, will be the predominant
criteria for determining funding priorities.  However, after
applications have been approved by the National Advisory Allergy and
Infectious Diseases Council, NIAID staff reserves the right to consider
the demographic features of the nationwide HIV epidemic among women and
study cost-efficiency.

INQUIRIES

Written and telephone inquiries concerning this RFA are encouraged.
The opportunity to clarify any issues or questions from potential
applicants is welcomed.  Direct inquiries regarding programmatic issues
and requests for the RFA to:

Dr. Sandra Melnick
Vaccine Trials and Epidemiology Branch
Division of AIDS
National Institute of Allergy and Infectious Diseases
Solar Building Room 2A28
6003 Executive Boulevard
Bethesda, MD  20892
FAX:  (301) 402-1506

Direct inquiries regarding fiscal matters to:

Ms. Jane Unsworth
Chief, AIDS Grants Management Section/DEA
National Institute of Allergy and Infectious Diseases
Solar Building Room 4B25
6003 Executive Boulevard
Bethesda, MD  20892
Telephone:  (301) 496-7075
FAX:  (301) 480-3780

Direct inquiries concerning the review process and requirements to:

Dr. Dianne Tingley
AIDS RRS/SRB
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Solar Building Room 4C16
Bethesda, MD  20892
Telephone:  (301) 496-0818
FAX:  (301) 402-2638

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No. 93.856, Microbiology and Infectious Disease Research and No.
93.855, Immunology, Allergic and Immunologic Diseases Research.  Awards
are made under authorization of the Public Health Service Act, Title
IV,Part A (Public Law 78-410, as amended by Public Law 99-158,42 USC
241 and 285) and administered under PHS grants policies and Federal
Regulations 42 CFR 52, 45 CFR Part 74,and 45 CFR Part 92.  This program
is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.

$$R7 END ************************************************************

$$R8 BEGIN CA-93-03 FULL-TEXT ***************************************

THERAPEUTIC STUDIES OF PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANCIES IN
ADULTS

NIH GUIDE, Volume 21, Number 41, November 13, 1992

RFA AVAILABLE:  CA-93-03

P.T. 34; K.W. 0715035, 0705055, 0740015, 0740020

National Cancer Institute

Letter of Intent Receipt Date:  January 15, 1993
Application Receipt Date:  March 10, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

The Cancer Therapy Evaluation Program (CTEP) and the Radiation Research
Program (RRP) of the Division of Cancer Treatment (DCT) at the National
Cancer Institute (NCI) invite applications for cooperative agreements
(U01) from consortia of institutions to perform Phase I and II clinical
evaluations of promising new chemotherapeutic or biologic agents for
the treatment of primary central nervous system (CNS) malignancies and
to perform ancillary laboratory studies of aspects of CNS tumor biology
with potential clinical implications.  Integrated packages of
individual applications are encouraged, with the lead institution of a
proposed consortium indicating which participating institutions will
provide organizational support, scientific leadership, laboratory
capabilities, and/or patient resources.  Each consortium of
institutions will be referred to as a CNS Consortium (CNSC) for the
purpose of this RFA.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Therapeutic Studies of Primary Central Nervous System Malignancies in
Adults, is related to the priority area of cancer.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report:
Stock No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, DC 20402-9325 (telephone
202/783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by North American non-profit and
for-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of State and local
governments, DCT clinical cooperative groups, and eligible agencies of
the Federal government.  Applications from minority individuals and
women are encouraged.

It is essential that applications be submitted as an integrated package
from a team or consortium (CNSC) of medical institutions (a minimum of
three) that agree to work together with a single Project Leader and a
single administration, and submit applications that will be reviewed in
relation to the consortium. Together, the institutions in the
consortium would encompass experience in investigational drug clinical
trials, access to sufficient numbers of primary CNS tumor patients to
enter a minimum of 60-80 fully evaluable cases per year onto Phase I
and II protocols, expertise in laboratory investigation of the biology
of human gliomas, and access to a Central Operations Office for
coordination of research activities and data analysis. Except under
unusual circumstances, the Central Operations Office/Coordinating
Center would be expected to reside at the Project Leader's institution.

MECHANISM OF SUPPORT

Awards will be made as cooperative agreements that create an assistance
relationship with substantial NCI programmatic involvement with the
recipients during the performance of the project, as outlined in this
RFA.  The cooperative agreement mechanism is used when the NCI wishes
to stimulate investigator interest and proposes to advise or assist in
an important and opportune area of research.

Support of this program will be through the Cooperative Agreement
(U01), an assistance mechanism in which substantial NCI programmatic
involvement with the recipient during performance of the planned
activity is anticipated.  The nature of NCI staff involvement is
described in the RFA.  Applicants will be responsible for the planning,
direction, and execution of the proposed project. Except as otherwise